RxDoctor Payments Data

Frank Louthan, MD

Pulmonary Disease · Murfreesboro, TNNPI 1609844489

Payments from drug & device makers

$501in general payments, 2019–2025

Across 23 payments — averaging $21.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$261
  • Inspire Medical Systems, Inc.$92
  • Insmed, Inc.$65
  • Edwards Lifesciences$31
  • Covidien LP$20
  • CSL Behring$19
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$43687%
  • Education$6513%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$501 in reported general payments places this provider in the 20th percentile of 339 pulmonary disease providers in Tennessee.

See all pulmonary disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$59,335
Medicare patients
243
Services billed
585

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter199$170,692
Breo ElliptaFluticasone/Vilanterol137$67,277
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr74$38,308
Spiriva HandihalerTiotropium Bromide20$14,873
Spiriva RespimatTiotropium Bromide17$14,090
Tiotropium Bromide28$11,829
Stiolto RespimatTiotropium Br/Olodaterol Hcl17$10,797
SymbicortBudesonide/Formoterol Fumarate13$7,459
Fluticasone-SalmeterolFluticasone Propion/Salmeterol60$6,427
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate21$6,265
Albuterol Sulfate HfaAlbuterol Sulfate232$5,314
Wixela InhubFluticasone Propion/Salmeterol35$5,270
Incruse ElliptaUmeclidinium Bromide11$4,480
Advair DiskusFluticasone Propion/Salmeterol13$2,524
Ventolin HfaAlbuterol Sulfate18$1,615

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$261$280,757421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 339 pulmonary disease providers in Tennessee.

Other pulmonary disease in Murfreesboro

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →